Share this postThe Drug Development LetterThe CABINET studyCopy linkFacebookEmailNotesMorePlayback speed×Share postShare post at current timeShare from 0:000:00/0:00Transcript27Share this postThe Drug Development LetterThe CABINET studyCopy linkFacebookEmailNotesMore31The CABINET study100% NIH funded; 100% placebo controlledVinay PrasadFeb 21, 202527Share this postThe Drug Development LetterThe CABINET studyCopy linkFacebookEmailNotesMore31ShareTranscriptDiscussion about this videoCommentsRestacksShare this postThe Drug Development LetterThe CABINET studyCopy linkFacebookEmailNotesMoreThe Drug Development LetterSubscribeAuthorsVinay PrasadRecent PostsCDK4/6 Inhibitors and Novel Adjuvant Therapies: Using Statistics to Inform Shared Decision-Making Mar 4 • Timothée OlivierRANDOMIZED versus REAL-WORLD EVIDENCE ON THE EFFICACY AND TOXICITY OF CHECKPOINT INHIBITORS.Dec 15, 2024 • Timothée OlivierSpecial post-ESMO 2024 edition !Nov 3, 2024 • Vinay Prasad and Timothée OlivierSpecial ESMO 2024 edition !Sep 14, 2024 • Vinay Prasad and Timothée OlivierDriver mutation lung cancerSep 9, 2024 • Vinay PrasadSpecial post-ASCO 2024 edition !Jun 9, 2024 • Vinay Prasad and Timothée OlivierASCO pre-game showMay 30, 2024 • Vinay Prasad
Share this post